Tevogen Bio Holdings Inc. Common Stock (TVGN)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with the business, not the story. Tevogen is a clinical-stage immunotherapy company with 18 employees, developing off-the-shelf T cell therapies. It reported no revenue in the filed periods I can see. In fiscal 2025, the year ended 2025-12-31, it lost $26.3 million, or $8.08 per diluted share. Fiscal 2024, ended 2024-12-31, lost $13.7 million, or $3.50 per share; fiscal 2023, ended 2023-12-31, lost $60.5 million, or $2.44 per share. Recent quarters show the same pattern: fiscal Q2 2026, the quarter ended 2026-06-30, lost $5.8 million, or $1.52 per share, while fiscal Q1 2026, ended 2026-03-31, lost $5.4 million, or $1.61 per share. Trailing free cash flow is negative $11.6 million, which FairStock calculates as a negative 25.1% free cash flow yield against the $46.3 million market cap at the 2026-10-13 close of $7.11. FairStock also shows P/E of -1.05, ROCE of -297.37%, a Piotroski score of 1/9, and an Altman Z-score of -43.69. Those are not marks of financial strength. The moat, if any, is not visible in the numbers; it depends on clinical success for TVGN 489 and future approvals or partnerships. I see no revenue, no profits, heavy cash burn, and no margin of safety from current earnings. The stock may be a lottery ticket on science, but it is not a Graham-style value investment at this price.

In plain English: Tevogen Bio Holdings is a small healthcare company that is testing cell-based treatments for infectious diseases and cancer. It has no reported revenue in the filed periods and has been losing money, with cash going out faster than it comes in. At $7.11, the stock is not supported by current profits or cash coming in, so it looks speculative rather than cheap based on today's numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer